BridgeBio Oncology Therapeutics, Inc.
BBOT
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$172M
▼ -80.5% YoY
Op. Margin
–
ROIC
-41.93%
▲ +23044.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$151M
▼ -107.9% YoY
Op. Cash Flow (TTM)
-$151M
▼ -107.0% YoY
Net Debt
-$191M
Net Cash Position
Cash & Equiv.
$194M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with BBOT
Held by ETFs
BBOT is in 7 US ETFs. The largest of them, with BBOT's weight in each:
State Street SPDR S&P Biotech ETFXBI0.02%of the fund
iShares Biotechnology ETFIBB0.01%of the fund
Direxion Daily S&P Biotech Bull 3X SharesLABU0.05%of the fund
- CATema Oncology ETFCANC0.48%of the fund
- BBVirtus Biotech Clinical Trials ETFBBC0.70%of the fund
Harbor Active Small Cap Growth ETFSGRW0.37%of the fund
BridgeBio Oncology Therapeutics (BBOT) in two numbers
Questions about BridgeBio Oncology Therapeutics
Does BridgeBio Oncology Therapeutics (BBOT) pay a dividend?
No. BridgeBio Oncology Therapeutics (BBOT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 5 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BBOT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BBOT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.